HC Wainwright Issues Positive Forecast for NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target increased by research analysts at HC Wainwright from $40.00 to $45.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the company. Zacks Research downgraded NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $38.00.

NRx Pharmaceuticals Stock Up 1.1%

NASDAQ:NRXP traded up $0.02 during mid-day trading on Tuesday, hitting $1.83. 315,236 shares of the company traded hands, compared to its average volume of 1,155,314. The stock’s fifty day moving average price is $2.13 and its 200-day moving average price is $2.52. The firm has a market cap of $58.17 million, a price-to-earnings ratio of -0.78 and a beta of 1.91. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter valued at $994,000. Geode Capital Management LLC increased its holdings in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after buying an additional 33,004 shares during the last quarter. State Street Corp raised its position in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter worth about $107,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.